A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study (Q35748507)
Jump to navigation
Jump to search
scientific article published on 14 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study |
scientific article published on 14 April 2015 |
Statements
1 reference
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study (English)
1 reference
Robert L Coleman
1 reference
Michael W Sill
1 reference
Premal H Thaker
1 reference
David P Bender
1 reference
Daron Street
1 reference
William P McGuire
1 reference
Carolyn M Johnston
1 reference
Jacob Rotmensch
1 reference
14 April 2015
1 reference
1 reference
1 reference
Identifiers
1 reference